Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Experimental Dermatology|May 9, 2025
Blocking of IL-4/IL-13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton SyndromeStefan Blunder, Natascha Hermann-Kleiter, Rita Mahmuti, et al.
Cell Communication and Signaling : CCS|July 29, 2016
Role of PKCtheta in macrophage-mediated immune response to Salmonella typhimurium infection in miceChrista Pfeifhofer-Obermair, Karin Albrecht-Schgoer, Sebastian Peer, et al.
Immunity|August 15, 2008
The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunityNatascha Hermann-Kleiter, Thomas Gruber, Christina Lutz-Nicoladoni, et al.
Frontiers in Immunology|April 3, 2024
Silicone implant surface microtopography modulates inflammation and tissue repair in capsular fibrosisInes Schoberleitner, Klaus Faserl, Christoph H Tripp, et al.
Gut|September 8, 2017
NAD metabolism fuels human and mouse intestinal inflammationRomana R Gerner, Victoria Klepsch, Sophie Macheiner, et al.
Molecular Immunology|April 10, 2009
PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivoThomas Gruber, Natascha Hermann-Kleiter, Christa Pfeifhofer-Obermair, et al.
Nature Communications|April 20, 2018
Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockadeVictoria Klepsch, Natascha Hermann-Kleiter, Patricia Do-Dinh, et al.
The Journal of Investigative Dermatology|June 12, 2020
Notch-Mediated Generation of Monocyte-Derived Langerhans Cells: Phenotype and FunctionLydia Bellmann, Claudia Zelle-Rieser, Paul Milne, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 4, 2009
The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activationJean-Pierre Evenou, Jürgen Wagner, Gerhard Zenke, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanomaFlorian Hornsteiner, Janine Vierthaler, Helen Strandt, et al.
Pageof 5